Modern approaches to the assessment of orally inhaled products bioequivalence

The article analyses regulatory documents containing requirements for clinical (trials) documentation for orally inhaled products, including requirements for the demonstration of therapeutic equivalence of medicinal products for the treatment of bronchial asthma and chronic obstructive pulmonary disease in adults and children. The article summarises the main approaches to the assessment of inhalers equivalence. It also systematizes and describes dosage forms and inhalation devices, as well as the necessary stages of inhaler evaluation, looks into the methodology of conducting therapeutic equivalence studies with due regard to the therapeutic class of the drug, duration of its action and proposed nosology. The methodology includes requirements for the selection of the study population, study design and conditions, and recommendations for the selection of drug dose, study duration, primary and secondary efficacy and safety endpoints in the context of orally inhaled products.

ингаляционные лекарственные препараты, ингаляционные устройства, фармакокинетика, фармакодинамика, биоэквивалентность, терапевтическая эквивалентность, конечные точки клинических исследований, критерии оценки эффективности и безопасности, orally inhaled products, inhalation devices, pharmacokinetics, pharmacodynamics, bioequivalence, therapeutic equivalence, primary endpoints of clinical trials, efficacy and safety criteria

1. Global initiative for chronic obstructive lung disease (GOLD) [Internet]. 2017 [cited 2017 Jul 3]. Available from: http://www.goldcopd.org.

2. Global Initiative for Asthma (GINA). 2015 [cited 2017 Jul 3]. Available from: http://www.ginasthma.org.

3. Mitkina LI, Kovaleva EL, Prokopov IA. Standardization of inhalation dosage forms in the Russian Federation: current status and perspectives. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2012; (1): 53–7 (in Russian).

4. General monograph 1.1.0012.15. Inhalation drug products. State Pharmacopoeia of the Russian Federation. XIII ed. Ì.; 2015. Available from: http://femb.ru/feml.

5. General monograph 1.4.2.001.15. Aerodynamic particle size distribution. State Pharmacopoeia of the Russian Federation. XIII ed. Ì.; 2015. Available from: http://femb.ru/feml.

6. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents Doc. Ref. CPMP/EWP/4151/00 Rev. 1. London; 2009. Available from: https://goo.gl/ZzEkwi.

7. Olefir YuV. The results of the analysis on materials of safety of clinical trials. Safety and Risk of Pharmacotherapy 2017; 5(1): 5–10 (in Russian).

8. Nonikov VE, Arkhipov VV, Marinin VF, Cheltsov VV, Berdnikova NG, Petrova ES. Guideline on conducting clinical trials of inhaled glucocorticosteroids. In: Guidance on clinical evaluation of medicines. Part I. Moscow: Grif i K; 2012. P. 177–86 (in Russian).